Abstract
There are proposals for the implementation of beta(2)-adrenoceptor agonists for the management of muscle wasting diseases. The idea has been initiated by studies in animal models which show that beta(2)-adrenoceptor agonists cause hypertrophy of skeletal muscle. Their use in clinical practice will also need an understanding of possible effects of activation of human heart beta(2)-adrenoceptors. Consequences could include an increased probability of arrhythmias in susceptible patients.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adrenergic beta-2 Receptor Agonists*
-
Adrenergic beta-Agonists / therapeutic use*
-
Animals
-
Heart / drug effects*
-
Heart Diseases / drug therapy
-
Humans
-
Muscle, Skeletal / drug effects*
-
Muscle, Skeletal / metabolism
-
Muscular Dystrophies / drug therapy*
-
Myocardium / metabolism
-
Receptors, Adrenergic, beta-1 / metabolism
-
Receptors, Adrenergic, beta-2 / metabolism
Substances
-
Adrenergic beta-2 Receptor Agonists
-
Adrenergic beta-Agonists
-
Receptors, Adrenergic, beta-1
-
Receptors, Adrenergic, beta-2